Published in J Clin Transl Hepatol on September 25, 2016
Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol (2011) 17.11
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol (1994) 8.98
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63
EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol (2015) 5.75
Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol (2003) 5.41
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology (2003) 4.21
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med (1992) 4.05
The M2 proton channels of influenza A and B viruses. J Biol Chem (2005) 3.49
AASLD guidelines for treatment of chronic hepatitis B. Hepatology (2015) 3.32
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Viroporins. FEBS Lett (2003) 2.57
Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci (1999) 2.50
Hepatitis B: the virus and disease. Hepatology (2009) 2.48
Homologous sequences in non-structural proteins from cowpea mosaic virus and picornaviruses. EMBO J (1984) 2.35
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Hepatitis B virus replication. World J Gastroenterol (2007) 2.30
Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J (1997) 2.09
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Protection against hepatitis A by an inactivated vaccine. JAMA (1994) 1.99
Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA. J Gen Virol (2003) 1.97
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog (2009) 1.94
Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med (2007) 1.89
Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ (2008) 1.86
Molecular virology of hepatitis E virus. Virus Res (2011) 1.80
Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus. J Virol (1994) 1.78
Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology (2007) 1.71
Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother (1999) 1.63
Hepatitis A virus: from discovery to vaccines. Hepatology (2006) 1.63
Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther (2010) 1.61
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis (2015) 1.59
Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology (2012) 1.55
The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids (2014) 1.46
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int (2009) 1.46
Morphogenesis of hepatitis A virus: isolation and characterization of subviral particles. J Virol (1990) 1.44
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology (2010) 1.43
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther (2013) 1.42
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res (2008) 1.40
Hepatitis C virus entry into host cells. Cell Mol Life Sci (2008) 1.40
An overview of HCV molecular biology, replication and immune responses. Virol J (2011) 1.37
Vertical transmission of hepatitis E virus. Lancet (1995) 1.34
Hepatitis C virus entry: molecular biology and clinical implications. Hepatology (2006) 1.34
Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother (2012) 1.31
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol (2012) 1.29
Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem Biol (2010) 1.21
A very late viral protein triggers the lytic release of SV40. PLoS Pathog (2007) 1.20
Treatment of severe acute hepatitis E by ribavirin. J Clin Virol (2011) 1.18
Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med (2010) 1.17
Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol (2014) 1.13
Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep (2013) 1.12
Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. J Virol (2009) 1.12
Alphavirus 6K proteins form ion channels. J Biol Chem (2002) 1.10
An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther (2013) 1.10
Systemic viral infections and collateral damage in the liver. Am J Pathol (2006) 1.10
Identification and site-directed mutagenesis of the primary (2A/2B) cleavage site of the hepatitis A virus polyprotein: functional impact on the infectivity of HAV RNA transcripts. Virology (1995) 1.09
Analysis of deletion mutants indicates that the 2A polypeptide of hepatitis A virus participates in virion morphogenesis. J Virol (2002) 1.09
Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis (1991) 1.09
The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons. J Virol (1999) 1.08
β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res (2013) 1.07
Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc Natl Acad Sci U S A (2006) 1.07
Possible function for virus encoded K+ channel Kcv in the replication of chlorella virus PBCV-1. FEBS Lett (2003) 1.01
The molecular virology of hepatitis B virus. Semin Liver Dis (2013) 1.01
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol (2013) 0.99
Infectious bursal disease virus, a non-enveloped virus, possesses a capsid-associated peptide that deforms and perforates biological membranes. J Biol Chem (2007) 0.99
Molecular biology and replication of hepatitis E virus. Emerg Microbes Infect (2012) 0.97
Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrob Agents Chemother (2014) 0.97
Oligomerization state and supramolecular structure of the HIV-1 Vpu protein transmembrane segment in phospholipid bilayers. Protein Sci (2010) 0.97
New therapeutic strategies in HCV: polymerase inhibitors. Liver Int (2013) 0.94
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother (2014) 0.94
Management of acute hepatitis B. Clin Liver Dis (2010) 0.94
Proteoglycans act as cellular hepatitis delta virus attachment receptors. PLoS One (2013) 0.94
Maturation of the hepatitis A virus capsid protein VP1 is not dependent on processing by the 3Cpro proteinase. J Virol (1999) 0.92
Current management of hepatitis B virus infection before and after liver transplantation. Liver Int (2009) 0.92
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res (2015) 0.92
Characterization of recombinant hepatitis A virus genomes containing exogenous sequences at the 2A/2B junction. J Virol (2001) 0.91
Membrane integration of poliovirus 2B viroporin. J Virol (2011) 0.91
Role of heat-shock protein 90 in hepatitis E virus capsid trafficking. J Gen Virol (2010) 0.91
The coronavirus E protein: assembly and beyond. Viruses (2012) 0.88
Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother (2015) 0.87
Hepatitis B virus: from diagnosis to treatment. Pathol Biol (Paris) (2010) 0.86
Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation. Cell Microbiol (2010) 0.85
Homology model and potential virus-capsid binding site of a putative HEV receptor Grp78. J Mol Model (2010) 0.85
The minimalist architectures of viroporins and their therapeutic implications. Biochim Biophys Acta (2013) 0.84
Viroporins: structure, function and potential as antiviral targets. J Gen Virol (2015) 0.84
The elusive function of the hepatitis C virus p7 protein. Virology (2014) 0.83
Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. Int J Mol Sci (2015) 0.83
HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) (2015) 0.82
Life cycle and pathogenesis of hepatitis D virus: A review. World J Hepatol (2013) 0.82
Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. PLoS One (2015) 0.82
The VP4 peptide of hepatitis A virus ruptures membranes through formation of discrete pores. J Virol (2014) 0.82
A review of hepatitis B vaccination. Expert Opin Drug Saf (2003) 0.81